Haisco Pharma receives IND acceptance for HSK47388 tablet

Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) announced that it has received an "Acceptance Notice" from the National Medical Products Administration for its innovative drug, HSK47388 tablets. The Investigational New Drug (IND) application covers a new indication for the treatment of autoimmune diseases. HSK47388 is an orally administered drug developed by Haisco, designed for high efficacy and selectivity. Preclinical studies have demonstrated significant dose-dependent efficacy in rat colitis models, coupled with good tolerability and a large safety window. This application seeks approval for clinical trials evaluating HSK47388 in autoimmune disorders, potentially offering a novel treatment option for patients. The company acknowledged the risks inherent in drug development, including lengthy timelines and various uncertainties, urging investors to exercise caution.